[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cystitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cystitis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100579319","phase-3-fosfomycin-for-male-urinary-tract-infection-100579319",false,"NCT06822751","FOsfomycin for Male Urinary Tract Infection","Exploratory Pragmatic Trial of Fosfomycin-trometamol Treatment of Male Urinary Tract Infections in Primary Care","FOMUTI","Inclusion Criteria:\n\n* Men aged 18 years or older.\n* Consulting in a primary care setting.\n* Suspected of having a male urinary tract infection (MUTI) by the investigating physician and presenting at least one recent acute symptom (\\\u003C 3 months) from the following:\n\n  * Lower urinary tract symptoms: dysuria, urgency, frequency, hematuria.\n  * Pelvic pain unrelated to urination: suprapubic, perineal, or urethral pain.\n* Patient has read and understood the information letter and signed the informed consent form.\n* Affiliation with a social security system or beneficiary of such a system.\n* No history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or to prevent him\u002Fher from giving informed consent\n\nExclusion Criteria:\n\n* Presence of one or more criteria for severity of infection\n\n  * Severe sepsis or septic shock defined by a qSOFA score ≥ 2\n  * or\u002Fand systolic BP less than 100 mmHg: non-inclusion criterion\n  * or\u002Fand temperature \\\u003C 36°C or \\> 38°C\n  * or\u002Fand diagnosis of pyelonephritis (pain on lumbar percussion)\n  * or\u002Fand presence of abdominal guarding\u002Fcontraction\n  * or\u002Fand presence of a bladder globe above the pubic bone: (suspected acute retention of urine)\n  * or\u002Fand known immunosuppression: any immunosuppressive treatment (including corticosteroid therapy \\> 10 mg\u002Fd for more than 5 days), neutropenia (PNN \\\u003C 500\u002FmL) severe malnutrition (albumin \\\u003C 30 and\u002For BMI \\\u003C 16),\n* No diagnosis of male urinary tract infection in the last 3 months,\n* No ongoing chronic prostatitis,\n* Known urinary tract abnormality: urinary tract lithiasis, vesico-ureteral reflux, prostate or urinary tract cancer, prostate adenoma treated medically or surgically, urinary tract malformation (including single kidney and urethral stricture).\n* Acute retention of urine and indication for surgical or interventional drainage\n* Hyperalgesic form\n* Urinary tract infection associated with care, on urinary catheter or suprapubic catheter\n* Urinary tract surgery, cystoscopy, prostate biopsy or urinary catheterisation less than 3 months old\n* Urinary tract surgery, cystoscopy, prostate biopsy or urinary catheterisation less than 3 months old\n* Severe disease or high probability of death within 3 months,\n* Hypersensitivity to fosfomycin trometamol or to any of the excipients (notable excipients: sucrose, dextrose (source of glucose), maltodextrin (source of glucose), orange yellow colouring S (E110)),\n* End-stage renal disease (creatinine clearance \\\u003C10 mL\u002Fmin),\n* Patients with glucose and galactose malabsorption syndrome or sucrase\u002Fisomaltase deficiency (rare hereditary disease)\n* Antibiotic taken within 72 hours of diagnosis of male urinary tract infection,\n* Major cognitive impairment,\n* Person deprived of liberty by an administrative or judicial decision or person placed under court protection \u002F sub- guardianship or curatorship\n* Any history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or to prevent the subject from giving informed consent.\n* Known non-adherence to treatment,\n* Simultaneous participation in another interventional clinical study,\n* Cannot be taken orally (vomiting)","MALE","18 Years",{"count":20,"type":21},138,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Male urinary tract infections (MUTI) are often less recognised compared to those in women. French clinical guidelines practices recommend the use of antibiotics called fluoroquinolones, which are highly effective in treating MUTIs. However, these antibiotics can lead to rare but serious side effects, such as tendonitis or heart rhythm disturbances. Additionally, fluoroquinolones can contribute to the development of bacterial resistance, making their use inadvisable within six months of treatment.\n\nIn response to these concerns, we aim to explore a well-established alternative, fosfomycin trometamol (known by the brand name MONURIL®). This antibiotic has a strong track record in treating UTIs in women, with well-documented benefits and minimal associated risks.\n\nThe primary goal of this study is to assess the effectiveness of fosfomycin trometamol in treating urinary tract infections in men, as well as to evaluate any potential treatment failures.",[27,28,29],"Urinary Tract Infection","Prostatitis","Cystitis",[31,29,27,32,33],"Men","Anti-infective agents, urinary","Fosfomycin","NOT_YET_RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":21},"2026-07",{"date":42,"type":21},"2029-10",{"name":44,"class":45},"University Hospital, Rouen","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100466989","hospital-at-home-for-elderly-acute-ill-patients-100466989","NCT05360914","Hospital at Home for Elderly Acute Ill Patients","Improving and Evaluation of a New Cross-sectoral Hospital at Home Model for Elderly Acute Ill Patients","Inclusion Criteria:\n\n* The patient should be aged 65 and over\n* Diagnosed with a stable acute medical conditions e.g. cystitis, erysipelas, pneumonia\n* The patient should be living in their own home or a nursing home before entering the study\n* The patient should be residing in one of the three municipalities (Viborg, Skive and Silkeborg)\n* The patient must have been seen by the GP or the pre-hospital service in the case of disease in question\n* The patient should speak and understand Danish.\n* The patient should give informed consent to participate in the study.\n\nExclusion Criteria:\n\n* The patient is unable to give written consent\n* The capacity of the municipal acut team care was fully utilised.","ALL","65 Years",{"count":57,"type":21},849,[59],"NA","Many elderly patients with uncomplicated treatment courses are admitted unnecessarily, which is a burden for the patient and society. Studies show that Hospital at Home (HaH) treatment is an alternative to hospitalization. The patient's risk of delirium, infection and loss of function is reduced when the patient avoids the hospital stay. HaH treatment is expected to be more cost-effective, improve patients' functional abilities and patients' satisfaction.\n\nThree municipalities, general practitioners, pre-hospital service and an emergency department (ED) in Central Denmark Region have organized the first HaH treatment model across disciplines and sectors. Specialists in the ED and the municipal acute teams provide HaH treatment for elderly acute ill patients. However, the model has not yet been evaluated.\n\nThe aim of this study is to optimize the HaH treatment model for elderly acute ill patients. The objective is to increase patient satisfaction and optimize the use of resources in healthcare by avoiding unnecessary hospitalizations that impair and prolong treatment.\n\nThis study is an open label randomized controlled trial (RCT) with a 1:2 allocation ratio of acute hospital admission versus HaH. During a pilot period, we tested and adapted the patient pathway of HaH to the practical reality, before we start the randomization for the RCT study. We will investigate the clinical effects and health economic consequences of HaH treatment compared with standard hospital treatment.",[29,62,63],"Erysipelas","Pneumonia","RECRUITING","2024-08-06",{"date":67,"type":38},"2024-08-09",{"date":69,"type":38},"2022-06-01",{"date":71,"type":21},"2027-08",{"name":73,"class":74},"Defactum, Central Denmark Region","OTHER_GOV",3]